Walleye Capital’s Akero Therapeutics AKRO Stock Holding History

Walleye Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,900	Closed	-$138K	–	4513
2025 Q3	$138K	Sell	2,900 -4,200	-59%	-$203K	﹤0.01%	3546
2025 Q2	$379K	Buy	+7,100	New	+$323K	﹤0.01%	2874
2024 Q3	–	Sell	-3,200	Closed	-$75.1K	–	5203
2024 Q2	$75.1K	Sell	3,200 -4,000	-56%	-$85.5K	﹤0.01%	4822
2024 Q1	$182K	Sell	7,200 -9,400	-57%	-$226K	﹤0.01%	4044
2023 Q4	$388K	Buy	+16,600	New	+$327K	﹤0.01%	3140
2023 Q3	–	Sell	-16,600	Closed	-$775K	–	4818
2023 Q2	$775K	Buy	+16,600	New	+$761K	﹤0.01%	2063
2023 Q1	–	Sell	-10,000	Closed	-$548K	–	3888
2022 Q4	$548K	Buy	+10,000	New	+$428K	0.01%	1392

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's AKRO Position: Q3 2025 in Review

Walleye Capital sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 3,323 shares — an estimated $161K sold.

Walleye Capital first reported a position in AKRO in Q3 2022 and held it in 10 quarters. The position peaked at $6.95M in Q3 2022. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

Walleye Capital reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 3,323 Akero Therapeutics shares in Q3 2025, an estimated $161K.
Walleye Capital first reported a position in Akero Therapeutics in Q3 2022 and held it in 10 quarters.
Walleye Capital's Akero Therapeutics position peaked at $6.95M in Q3 2022.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.